Oral Session 1-10C AML: FLT3 Inhibitors

[OS1-10C-2] Gilteritinib in combination with chemotherapy in Japanese patients with newly diagnosed AML

Toru Sakura¹, Hiroatsu Iida², Takayuki Ishikawa³, Kensuke Usuki⁴, Shin Fujisawa⁵, Toshihiro Miyamoto⁶, Satoshi Morita⁷, Bahceci Erkut⁸, Masahito Kaneko⁹, Takeshi Kadokura⁹, Musashi Fukuda⁹, Shuichi Miyawaki¹⁰, Tomoki Naoe² (1.Saiseikai Maebashi Hospit., Gunma Japan, 2.NHO Nagoya Medical Center, Nagoya, Japan, 3.Kobe City Medical Center General Hospital, 4.NTT Medical Center Tokyo, Tokyo, Japan, 5.Yokohama City University Medical Center, Japan, 6.Kyushu University, Fukuoka, Japan, 7.Kyoto University, Kyoto, Japan, 8.Astellas Pharma, US Inc., Northbrook, IL, USA, 9.Astellas Pharma, Inc., Tokyo, Japan, 10.Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan)